Roots Analysis
NOVEMBER 30, 2021
Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Bioassays are biochemical procedures that are used to evaluate the potency, purity and efficacy of a drug substance.
Drug Discovery World
FEBRUARY 23, 2023
Proteins are the basic building blocks and engines of biology. For decades, drug discovery and development have been constrained by limits in our knowledge of the relationship between protein sequence, structure and function, and the methods available to explore novel drug targets.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
JANUARY 16, 2023
In the health industry, digitization has evolved over time with numerous advances to ensure that everyone has equitable access to health products and medical specialists. You may also be interested in the following titles: Targeted protein degradation market , 2022-2035. Cell and Gene Therapy Bioassay Services Market, 2021-2030.
Drug Discovery World
NOVEMBER 9, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.
Drug Discovery World
MAY 4, 2023
The drug target for Penicillin is a protein that helps bacteria to synthesise its cell wall. One of the first and most basic requirements for a protein to be characterised as a drug target is to show that inhibiting its function prevents the disease. Salvarsan was soon overtaken by the Penicillin antibiotics.
Drug Discovery World
NOVEMBER 30, 2023
This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.
Drug Discovery World
JANUARY 19, 2023
However, standard technologies used to ensure the highest value cells are progressed require multistep operations and instruments, extensive hands-on time, and lengthy liquid handling processes, as well as complex, low throughput bioassays for functional validation and verification.
Expert insights. Personalized for you.
52 
Let's personalize your content